Biotech Candidates — April 26, 2026
Overview
Pharma large-caps deteriorating. GILD at RSI 30.9 — approaching capitulation at $130.40, -5.7% vs SMA20, golden cross barely holding. ABBV crashed to RSI 35.2 at $198.71, down trend, -7.3% vs SMA200. AMGN RSI 43 at $344.55 (weak-down, golden cross, +7.4% vs SMA200). REGN steady at $746.46 (RSI 45, weak-down golden cross, +11.6% vs SMA200). ISRG reversed hard — flipped to weak-up at RSI 55.8, $482.22, +4.4% vs SMA20. CRSP RSI 40.7 ($48.78) — strong-down death cross but off worst levels (+3.6% 30D). VRTX weak-down at $440.05, RSI 44.1. LLY came into scope: $883.96, RSI 38.3, down trend, -2.5% vs SMA200 — GLP-1 leader pulling back hard.
| Signal |
Reading |
| Overall |
🟡 Pharma under pressure; GILD/ABBV approaching oversold; ISRG only turnaround |
| Key insight |
LLY at RSI 38 offers the highest-conviction entry — GLP-1 monopoly on 16% pullback |
Candidates
| Ticker |
Price |
RSI |
Trend |
7D |
30D |
52wkHi |
Signal |
Take |
| LLY |
$883.96 |
38.3 |
down |
-4.3% |
-3.5% |
-22.1% |
GC |
GLP-1 monopoly. -4.0% vs SMA20. -2.5% vs SMA200. Golden cross intact. RSI approaching oversold. |
| GILD |
$130.40 |
30.9 |
weak-down |
-5.1% |
-5.7% |
-17.1% |
GC |
Approaching capitulation. -5.3% vs SMA20. +4.2% vs SMA200. Golden cross. Watch RSI 30. |
| ABBV |
$198.71 |
35.2 |
down |
-3.5% |
-3.3% |
-18.8% |
GC |
Pulled back hard. -4.0% vs SMA20. -7.3% vs SMA200. Golden cross. Down trend. |
| ISRG |
$482.22 |
55.8 |
weak-up |
+2.6% |
+2.6% |
-20.2% |
DC |
Reversed from death cross lows. +4.4% vs SMA20. -3.8% vs SMA200. Death cross still active. |
| AMGN |
$344.55 |
42.8 |
weak-down |
-2.5% |
-2.7% |
-11.9% |
GC |
Large-cap anchor. -1.2% vs SMA20. +7.4% vs SMA200. Golden cross. RSI 43 neutral. |
| REGN |
$746.46 |
45.2 |
weak-down |
-2.1% |
-1.4% |
-9.1% |
GC |
Most stable. -1.0% vs SMA20. +11.6% vs SMA200. Golden cross. Near 52wk high (-9.1%). |
| VRTX |
$440.05 |
44.1 |
weak-down |
-0.6% |
-5.6% |
-13.9% |
GC |
Vertex stable. -1.6% vs SMA20. +0.4% vs SMA200. Golden cross barely holding. |
| CRSP |
$48.78 |
40.7 |
strong-down |
-15.4% |
+3.6% |
-37.8% |
DC |
Gene editing broken. -6.7% vs SMA20. -13.8% vs SMA200. Death cross. Avoid. |
Action Matrix
| Action |
Stocks |
Why |
| ✅ STRONG BUY |
LLY |
RSI 38 + golden cross + GLP-1 moat. Best entry in 12 months |
| 📈 ACCUMULATE |
GILD |
RSI 31 approaching capitulation. +4.2% vs SMA200 cushion. Stage entries |
| 🔍 WATCH |
ABBV |
RSI 35, near oversold. Golden cross. Watch for RSI 30 entry |
| 🔒 HOLD |
REGN, AMGN |
Stable pharma anchors. Golden crosses intact |
| 🔍 WATCH |
ISRG |
Reversal candidate — RSI 56, weak-up. Death cross flip to watch |
| ❌ DON'T BUY |
CRSP |
-13.8% vs SMA200. Death cross. Gene editing thesis unresolved |
Key Changes vs 04/10
| Ticker |
Price 04/10 |
Price 04/26 |
Move |
Note |
| ISRG |
$450.02 |
$482.22 |
+7.2% |
RSI 35 → 56. Flipped to weak-up. Death cross still active but recovering. |
| GILD |
$140.70 |
$130.40 |
-7.3% |
RSI 50 → 31. Deteriorated to near-capitulation. |
| ABBV |
$210.23 |
$198.71 |
-5.5% |
RSI 44 → 35. Trend downgraded to down. |
| LLY |
— |
$883.96 |
NEW |
RSI 38. Down trend but golden cross and GLP-1 moat intact. Best new entry. |
| CRSP |
$37.38 |
$48.78 |
+30.5% |
RSI 33 → 41. Bounced hard. Still death cross strong-down. |
Key Discoveries
| Discovery |
Implication |
| GILD RSI 31 approaching capitulation zone |
Pharma defense thesis now requires RSI validation below 30 for staged entry |
| ISRG RSI 35 → 56 recovery |
Surgical robotics proving more resilient than feared |
| LLY at -22% from 52wk high with golden cross |
Rare entry in a generational compounder — GLP-1 TAM not impaired |
Open Questions
- Is GILD's decline fundamentals (pipeline?) or macro rotation out of healthcare?
- CRSP +30.5% from lows — bear rally or base? Watch SMA50 ($52.58) reclaim as confirmation.